Replacement, reduction and refinement alternatives to animal use in vaccine potency measurement

Models to measure potency in vaccine research and development and preclinical testing are frequently based on an immunization–challenge procedure in laboratory animals. These models have proven to be very instrumental in scientifically underpinning the correlation of protection of selected vaccine antigens and their efficacy. In vivo models in vaccine research and development are, for the time being, irreplaceable, although significant progress has been made in using in vitro prescreening tests to evaluate particular immunological parameters. For a long time, in vivo potency tests have been similarly relevant for routine vaccine lot-release testing. The design of a potency test, defined in most pharmacopeias, relied on a direct or indirect-challenge procedure in laboratory animals. For various reasons, there now is an increased interest in the development of alternatives to the current in vivo potency tests. Animal models have their limitations, with respect to their relevance, reliability, costs and moral acceptability. All alternative approaches have in common that they ultimately result in a refinement, reduction or replacement in the use of animals. The new models range from modifications of the existing in vivo test procedure (e.g., use of humane end points or serology instead of challenge) to in vitro antigen-quantification tests. A new paradigm in quality control of vaccines is the consistency approach. This approach is state-of-the-art in quality control of the new-generation vaccines and it is now finding its way into the quality control of traditional vaccines. The consistency approach implies the use of a set of parameters to constitute a product profile, which is monitored throughout production, and which guarantees that each lot released is similar to a manufacturer-specific vaccine of proven clinical efficacy and safety. Consistency relies heavily on the implementation of quality systems, such as good manufacturing practice and quality assurance, and on the use of in vitro analytical tools, such as immunochemical and physicochemical tests.

[1]  R. Prigge Experimentelle Untersuchungen über die Wirksamkeit von Diphtherie-Impfstoffen. III. Mitteilung1: Prinzipien der Wertbemessung von hochaktiven Impfstoffen , 1937 .

[2]  Knight Pa,et al.  Studies on the minimal number of animals required to achieve assurance of satisfactory potency in diphtheria and tetanus vaccines. , 1986 .

[3]  K. Cussler,et al.  The evaluation of humane endpoints in pertussis vaccine potency testing , 1999 .

[4]  D. Sesardic,et al.  Collaborative study for the validation of serological methods for potency testing of diphtheria toxoid vaccines-part 1. , 2004, Pharmeuropa bio.

[5]  Gideon Kersten,et al.  The Potential of Physicochemical and Immunochemical Assays to Replace Animal Tests in the Quality Control of Toxoid Vaccines , 2007, Alternatives to laboratory animals : ATLA.

[6]  M. Landys Chovel Cuervo,et al.  Validation of an in vitro potency test for the Cuban hepatitis B vaccine. , 2002, Developments in biologicals.

[7]  C. Hendriksen Reduction of Numbers of Animals Used in the Quality Control of Biologicals , 2004, Alternatives to laboratory animals : ATLA.

[8]  F. Bergamin,et al.  Essential role of antigen‐presenting cell‐derived BAFF for antibody responses , 2007, European journal of immunology.

[9]  H. J. Parish A History of Immunization , 1965 .

[10]  K. Cussler,et al.  [Clinical endpoints during rabies vaccine control tests]. , 2001, ALTEX.

[11]  K. Enssle,et al.  The Pertussis Serological Potency Test. Collaborative study to evaluatereplacement of the Mouse Protection Test. , 1999, Biologicals : journal of the International Association of Biological Standardization.

[12]  M. Huet,et al.  Antibody response of pregnant women to two different absorbed tetanus toxoids. , 1991, Vaccine.

[13]  Robert H Levis,et al.  Three Rs Approaches in the Quality Control of Inactivated Rabies Vaccines: The Report and Recommendations of ECVAM Workshop 481,2 , 2003, Alternatives to laboratory animals : ATLA.

[14]  M. L. C. Cuervo,et al.  Validation of an in vitro potency test for the Cuban hepatitis B vaccine. , 2002 .

[15]  Marlies Halder,et al.  The consistency approach for the quality control of vaccines. , 2008, Biologicals : journal of the International Association of Biological Standardization.

[16]  M. Eichelberger,et al.  FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. , 2008, Vaccine.

[17]  J. Copley,et al.  Animal experiments -- where do you draw the line?: let the people speak. , 1999, New scientist.

[18]  J. G. Kreeftenberg Report of an informal meeting about alternative methods for the potency control of the diphtheria and tetanus components in vaccines. , 1986, Developments in biological standardization.

[19]  K. McCullough,et al.  An in vitro immune response model to determine tetanus toxoid antigen (vaccine) specific immunogenicity: Selection of sensitive assay criteria. , 2006, Vaccine.

[20]  Kreeftenberg Jg Report of an informal meeting about alternative methods for the potency control of the diphtheria and tetanus components in vaccines. , 1986 .

[21]  P. A. Knight The evaluation of the response of guinea pigs to diphtheria toxoids. , 1974, Journal of biological standardization.

[22]  Balls Michael,et al.  The Validation of Alternative Test Methods , 1996 .

[23]  P. Wunderli,et al.  The rabies peripheral challenge test: more accurate determination of vaccine potency. , 2006, Vaccine.

[24]  J. van der Gun,et al.  Collaborative study on test systems to assess toxicity of whole cell pertussis vaccine. , 1997, Biologicals : journal of the International Association of Biological Standardization.

[25]  Bernard Metz,et al.  Reduction of animal use in human vaccine quality control: opportunities and problems. , 2002, Vaccine.

[26]  W. Russell,et al.  Ethical and Scientific Considerations Regarding Animal Testing and Research , 2011, PloS one.

[27]  Pharmeuropa Bio Collaborative study for the validation of serological methods for potency testing of tetanus toxoid vaccines for human use. , 2002, Pharmeuropa. Special issue biologicals.

[28]  A. Osterhaus,et al.  Rabies vaccine potency control: comparison of ELISA systems for antigenicity testing. , 1996, Journal of virological methods.

[29]  M. V. Mussett,et al.  A collaborative investigation of a potency assay for adsorbed tetanus vaccines based on the protection of mice from tetanic paralysis. , 1976, Journal of biological standardization.

[30]  L. Morrison Vaccines against genital herpes: progress and limitations. , 2002, Drugs.

[31]  J. van der Gun,et al.  The effects of reductions in the numbers of animals used for the potency assay of the diphtheria and tetanus components of adsorbed vaccines by the methods of the European pharmacopoeia. , 1987, Journal of biological standardization.

[32]  J. Sparkes,et al.  Reduction in animal usage for potency testing of diphtheria and tetanus toxoids. , 1986, Developments in biological standardization.

[33]  D. Sesardic,et al.  Serological assays as alternatives to the Ph Eur challenge test for batch release of tetanus vaccines for human use. , 1999, Developments in biological standardization.

[34]  K. Cussler,et al.  Humane endpoints in the efficacy testing of swine erysipelas vaccines. , 2003, ALTEX.

[35]  D. Sesardic,et al.  Collaborative study for the validation of serological methods for potency testing of diphtheria toxoid vaccine (part 2). , 2006, Pharmeuropa bio.

[36]  D. Straughan,et al.  Validation of alternative methods for the potency testing of vaccines. , 1998, Alternatives to laboratory animals : ATLA.

[37]  M. Duchêne,et al.  Release potency tests of hepatitis vaccines. , 1999, Developments in biological standardization.